FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells^[1].

FF-10502 (0.1 nM-10 μM; 72 hours) shows the growth inhibition of pancreatic cancer cell lines, with IC₅₀s of 59.9 nM, 39.6 nM, 68.2 nM, and 331.4 nM for BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2 cells, respectively^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

261.27

C₉H₁₂FN₃O₃S

184302-49-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shinji Mima, et al. FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135.